Jeff Ryckman, Associate Professor of Radiation Oncology at WVU Medicine Camden Clark Medical Center, shared a post on X:
“Just published in The Lancet: TORPEdO – the first phase 3 RCT designed specifically to test whether IMPT (proton beam) improves late function and QoL vs modern IMRT in oropharyngeal SCC.
Short answer: It doesn’t.
Long answer (with the numbers that matter):
Background: We cure most locally advanced OPSCC patients with IMRT + cisplatin, but late dysphagia, xerostomia, dysgeusia, and weight loss still wreck QoL.
Protons spare OARs beautifully on paper. Does that actually help patients?
TORPEdO was built to answer exactly that.
Design (UK, 20 centres, n=205):
Mostly p16+ (96%)
48% T3/4, 22% bilateral neck
2:1 randomization to 136 IMPT vs 69 IMRT
70 Gy/33 fx + 2× high-dose cisplatin
Co-primaries at 12 mo:
- Gastrostomy dependence OR ≥20% wt loss
- UW-QoL physical composite score (swallow/chew/taste/saliva/speech/appearance)
Modern planning + mandatory replanning in both arms. No half-measures.
Co-primary results (mITT):
Tube or severe wt loss: 18% IMPT vs 7% IMRT adj OR 2.80 (97.5% CI 0.75-10.4), p=0.079 (driven almost entirely by wt loss 18% vs 6%; tube dependence ~2% both arms)
UW-QoL physical score: 78.3 vs 77.1 diff +1.3 (97.5% CI -3.7 to 6.2), p=0.56
No difference.
Other key findings:
24-mo LRC: 94% IMPT vs 97% IMRT (p=0.24)
24-mo OS: 95% both arms (p=0.47)
Acute G3 RT toxicity lower with protons (50% vs 72%, especially mucositis 37% vs 54% and dysphagia 12% vs 24%)
Late G3 toxicity numerically higher with IMPT (mainly wt loss)
Fewer prophylactic PEGs in IMPT arm leads to less tube use during Rx but more wt loss later. Real-world nuance.
Even in the NTCP-enriched subgroup (51% of pts who “should” benefit most per Dutch model): still no UW-QoL difference.
Dosimetric wins for protons? Yes.
Clinically meaningful late benefit? Not here.
Bottom line for practice: In settings where proton therapy isn’t routine (most places), modern IMRT remains the standard of care for oropharyngeal SCC.
Excellent trial. Honest result. We now have level 1 data showing the theoretical advantages of IMPT did not translate into better long-term swallow function or QoL.
Congrats to the entire TORPEdO team
What do you think? Does this change how you talk to patients about proton referral? Or are there subgroups we’re still missing?
Drop your thoughts in comments.”
Other articles featuring Jeff Ryckman on OncoDaily.